Tanguy-Schmidt A, Avenel-Audran M, Croué A, Lissandre S, Dib M, Zidane-Marinnes M, Moles M-P, Hunault-Berger M
Service des maladies du sang, CHU d'Angers, 49933 Angers cedex 09, France.
Ann Dermatol Venereol. 2009 May;136(5):443-6. doi: 10.1016/j.annder.2008.11.021. Epub 2009 Apr 28.
Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients.
We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present.
The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.
硼替佐米是一种强效蛋白酶体抑制剂，用于复发或难治性多发性骨髓瘤患者，有效率为35%，中位缓解持续时间为12个月。已知有许多不良反应，主要包括血液学和神经学并发症。10%至20%的患者还出现了各种各样的皮肤并发症。
我们报告一例硼替佐米诱发的Sweet综合征病例。该病例符合药物诱发Sweet综合征所需的诊断标准。
本病例描述的重要之处在于，这种诱发的Sweet综合征不一定需要停用硼替佐米，因为使用皮质类固醇可防止其复发。
